优化药物治疗下慢性心力衰竭中功能性二尖瓣反流的预后影响细化
该前瞻性观察研究纳入576例连续HFrEF患者,在优化药物治疗下随访中位62个月,47%死亡。严重FMR是全因死亡的独立预测因子(HR 1.76, 95%CI 1.34-2.30),且在NYHA II-III级、中度左室功能减低及NT-proBNP第二四分位区间(871-2360 pg/mL)的中间衰竭表型中预后影响最显著。
要点
- 严重FMR是HFrEF患者全因死亡的独立预测因子,校正临床、超声、药物及神经激素因素后仍显著。
- FMR的不良预后影响主要集中在NYHA II-III级、中度左室功能减低的中间衰竭表型。
- NT-proBNP 871-2360 pg/mL区间的患者中,严重FMR与预后显著相关。
核心结论
- 在优化药物治疗的HFrEF患者中,严重FMR的 adverse 预后影响主要存在于一个功能、血流动力学、生化和形态学上明确的中间衰竭表型亚组。
研究设计与样本
- 前瞻性纳入576例连续HFrEF患者,进行长期观察性研究,基线评估功能(NYHA分级)、超声心动图、侵入性血流动力学和生化指标。
- 中位随访62个月(四分位距52-76个月),47%患者死亡。
主要发现
- 严重FMR是全因死亡的显著预测因子(HR 1.76, 95%CI 1.34-2.30; P<0.001)。
- 校正临床混杂因素后HR 1.61(95%CI 1.22-2.12; P=0.001),校正超声心动图混杂因素后HR 1.46(95%CI 1.09-1.94; P=0.01)。
- 校正优化药物治疗后HR 1.81(95%CI 1.25-2.63; P=0.002),校正神经激素激活后HR 1.38(95%CI 1.03-1.84; P=0.03)。
- 亚组分析显示,严重FMR在NYHA II级(校正HR 2.17, 95%CI 1.07-4.44; P=0.03)和III级(校正HR 1.80, 95%CI 1.17-2.77; P=0.008)患者中与不良预后相关。
- 在中度左室功能减低(校正HR 2.37, 95%CI 1.36-4.12; P=0.002)及NT-proBNP第二四分位区间(871-2360 pg/mL;校正HR 2.16, 95%CI 1.22-3.86; P=0.009)患者中,严重FMR与不良预后相关。
临床怎么用
- 在HFrEF患者中,应关注严重FMR的预后意义,尤其在NYHA II-III级、中度左室功能减低及NT-proBNP中等升高的中间衰竭表型患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Significant efforts are currently undertaken to reduce functional mitral regurgitation (FMR) in patients with chronic heart failure in the hope to improve prognosis. We aimed to assess the prognostic impact of FMR in heart failure with reduced ejection fraction (HFrEF) under optimal medical therapy (OMT) and various conditions of HFrEF. We further intended to identify a heart failure phenotype, where FMR is most likely a driving force and not a mere bystander of the disease. METHODS AND RESULTS: We prospectively included 576 consecutive HFrEF patients into our long-term observational study. Functional [i.e. New York Heart Association (NYHA) class], echocardiographic, invasive haemodynamic, and biochemical (i.e. NT-proBNP, MR-proANP, MR-proADM, CT-proET-1, copeptin) measurements were performed at baseline. During a median follow-up of 62 months (interquartile range 52-76), 47% of patients died. Severe FMR was a significant predictor of mortality [hazard ratio (HR) 1.76, 95% confidence interval (CI) 1.34-2.30; P < 0.001], independent of clinical (adjusted HR 1.61, 95% CI 1.22-2.12; P = 0.001), and echocardiographic (adjusted HR 1.46, 95% CI 1.09-1.94; P = 0.01) confounders, OMT (adjusted HR 1.81, 95% CI 1.25-2.63; P = 0.002), and neurohumoral activation (adjusted HR 1.38, 95% CI 1.03-1.84; P = 0.03). Subanalysis revealed that severe FMR was associated with poor outcome in an intermediate-failure phenotype of HFrEF i.e. patients with NYHA class II (adjusted HR 2.17, 95% CI 1.07-4.44; P = 0.03) and III (adjusted HR 1.80, 95% CI 1.17-2.77; P = 0.008), moderately reduced left ventricular function (adjusted HR 2.37, 95% CI 1.36-4.12; P = 0.002), and within the second quartile (871-2360 pg/mL) of NT-proBNP (adjusted HR 2.16, 95% CI 1.22-3.86; P = 0.009). CONCLUSION: In a patient cohort under OMT, the adverse prognostic impact of FMR is given predominantly in a sub-cohort of a specific intermediate-failure phenotype-well-defined functionally, haemodynamically, biochemically, and morphologically.
引用
- Goliasch G, Bartko PE, Pavo N, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2018. PMID: 29020337. doi:10.1093/eurheartj/ehx402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。